Acrux is a differentiated drug delivery specialist targeting global markets and licensee partners.
We are raising our fair value estimate for Acrux to AUD 0.15 from AUD 0.13, after incorporating forward currency assumptions for USD/AUD exchange rates and remain cautiously optimistic on the upcoming filing of the first of 12 generic product candidates for the U.S. Food and Drug Administration, or FDA, with approval expected imminently. This will represent the first generic product for the company developed in-house to reach filing stage since Axiron back almost a decade ago. Two more filings a...Acrux is a pharmaceutical company engaged in the development and commercialization of specialty and generic transdermal and topical pharmaceuticals for global markets. Co.'s topical or transdermal pharmaceutical product portfolio can be segregated into two streams - generic pharmaceutical products and specialty pharmaceutical products.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.